
Legislation to remove financial barrier for organ donors; the Cell and Gene Therapy Access Model; trends in severe maternal morbidity – Morning Medical Update
Key Takeaways
- The Expanding Support for Living Donors Act seeks to remove financial barriers by increasing reimbursement and adjusting income eligibility for donors.
- The Cell and Gene Therapy Access Model aims to improve access to gene therapies for sickle cell disease, involving outcomes-based agreements with drug manufacturers.
The top news stories in medicine today.
Representatives Suzan DelBene (WA-01), Larry Bucshon, MD (IN-08), Kim Schrier, MD (WA-08) and Carol Miller (WV-01) have introduced the Expanding Support for Living Donors Act to address the increasingly high costs of donations.
“Donors give the gift of life to their fellow Americans, but for too long the system hasn’t been designed to fully support them,” DelBene said in a
Two drug manufacturers with U.S. Food and Drug Administration (FDA)-approved gene therapies for sickle cell disease have agreed with the Centers for Medicare & Medicaid Services (CMS) to participate in the Cell and Gene Therapy Access Model, a voluntary model that will test outcomes-based agreements for cell and gene therapies to increase health outcomes and access to cell and gene therapies and decrease health care costs.
“The Cell and Gene Therapy Access Model will increase access to promising therapies that improve the chances of people living longer, healthier lives,” Chiquita Brooks-LaSure, CMS administrator, said in a
A recent Agency for Healthcare Research and Quality (AHRQ) report included a
Newsletter
Stay informed and empowered with Medical Economics enewsletter, delivering expert insights, financial strategies, practice management tips and technology trends — tailored for today’s physicians.



















